ADMA Biologics (ADMA) Earnings Analysis
ADMA Biologics (ADMA) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it beat with EPS 0.2 USD vs 0.185 USD est (+8.1%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E 12.14.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ADMA next report earnings?
No confirmed upcoming earnings date is currently scheduled for ADMA. This page updates as the calendar is published.
ADMA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 0.2 USD | 0.185 USD | +8.1% | Beat |
| 2025-03-03 | 0.14 USD | 0.15 USD | -6.7% | Miss |
| 2024-11-07 | 0.15 USD | 0.13 USD | +15.4% | Beat |
| 2024-08-08 | 0.13 USD | 0.08 USD | +62.5% | Beat |
Beat rate: 3/4 (75%) over reported quarters with consensus data.
ADMA valuation and analyst view
| Trailing P/E | 12.14 |
|---|---|
| Trailing EPS | 0.70044 USD |
| Price / book | 5.07 |
| Dividend yield | 0.00% |
| Market cap | 1.95B |
| Analyst consensus | Buy (9 buy / 1 hold / 0 sell) |
| Avg price target | 18.67 USD |
Related research pages
Frequently asked questions
When is ADMA Biologics (ADMA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ADMA. This page updates as the calendar is published.
Did ADMA beat earnings last quarter?
In its 2026-02-25 report, ADMA posted EPS of 0.2 USD versus a 0.185 USD estimate — a beat of 8.1%.
What is ADMA's earnings track record?
Over the last 4 reported quarters with consensus data, ADMA beat estimates 3 times (75%).
What is ADMA's current P/E ratio and EPS?
ADMA trades at a trailing P/E of 12.14 on trailing EPS of 0.7004366209126779 USD.
What do analysts rate ADMA?
Analyst consensus is "Buy" across 10 ratings (1 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 18.67 USD.